Yale-Led Trial Shows Significant Disease-Free Survival For Patients Diagnosed With Non-Small Cell Lung Cancer
February 01, 2023
February 01, 2023
NEW HAVEN, Connecticut, Feb. 1 (TNSjou) -- Yale School of Medicine issued the following news:
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, and for patients diagnosed with more advanced disease stages, cases tend to recur.
The phase III ADAURA clinical trial assess . . .
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, and for patients diagnosed with more advanced disease stages, cases tend to recur.
The phase III ADAURA clinical trial assess . . .